Infinity Pharmaceuticals Announces Agreement With AstraZeneca

Infinity Pharmaceuticals, Inc. announced that Infinity has regained from MedImmune, which is wholly owned by AstraZeneca PLC, all development and worldwide commercialization rights for Infinity’s Hedgehog cell-signaling pathway inhibitor program, including its lead candidate IPI-926.
BioSpace